Latest
Sources
Trade Ideas
Speakers
Sign in
Go
Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)
Original source ↗
| February 11, 2026 at 11:45 UTC |
Finnhub - MRK
No analysis available.
Trade Ideas
Ticker
Direction
Speaker
Thesis
Time
MRK
NONE
Finnhub News
—
—